A case series analysis of data from the MOVING-MS study supports the use of the Multiple Sclerosis Disease Activity (MSDA) test as a reliable tool to reflect disease activity in various real-world clinical scenarios for patients with multiple sclerosis (pwMS). The findings, presented using multimodal data from the Octave Platform, reinforce the potential role of MSDA in informing management between standard clinical visits.

The study evaluated 36 participants from the MOVING-MS parent trial. These individuals were selected based on data completeness and availability of MSDA scores within ±30 days of events such as disease-modifying therapy (DMT) switches, pseudo-relapses, symptom fluctuations, and clinical stability.

Participants had a mean age of 42 years, with 83% identifying as female. Categorization included 6% undergoing DMT switches, 19% with pseudo-relapses, 3% with both, 33% experiencing symptom fluctuations, and 39% deemed clinically stable.

Findings demonstrated that most MSDA scores remained low to moderate during follow-up, aligning with clinical assessments, imaging findings, and absence of confirmed relapses. Importantly, in both DMT switch cases, MSDA scores decreased after the transition. Cases with symptom fluctuations but no relapses showed consistently low or moderate MSDA scores, mirroring their stable imaging and clinical status. 

This case series demonstrates that MSDA scores align with real-world MS management scenarios and may aid clinicians in monitoring disease activity between standard visits. The study also found that pseudo-relapse cases, defined by symptom exacerbations in the presence of external stressors such as infection or heat, did not show increases in MSDA scores, suggesting that the assay can distinguish between true inflammatory activity and transient symptom flares.

Detailed case timelines were created to illustrate the MSDA’s trajectory alongside other data streams, including quantitative MRI and nurse care partner insights. These multisource reports were collected using the Octave Care mobile application.

By integrating the MSDA test into routine monitoring, clinicians may be able to identify early signals of disease activity or confirm stability, potentially leading to more timely interventions and improved outcomes for pwMS.

Reference
Shabi T, Hua H, Miner A, et al. Measuring outcomes and value: an integrated, novel solution for generating insights in MS (MOVING-MS) study: case trajectories supported by multi-modal insights. Presented at: CMSC 2025; May 28-31; Phoenix, AZ.